ApoGen is initially focusing its drug development efforts on an antiviral component of the human innate immune system, the Apobec cytidine deaminases, which have been implicated as a prominent source of mutations in cancers.
ApoGen's drug discovery and development efforts are directed toward highly selective and potent small molecule inhibitors of the APOBEC family of enzymes, which are DNA cytosine deaminases and an important endogenous source of DNA mutations in cancer.
Editing is catalyzed by two classes of deaminases
: those which convert adenosine to inosine (ADARs) and those which convert cytosine to uracil (APOBEC1).
The proteins, known as APOBEC cytidine deaminases
, cause clusters of mutations that can outnumber all others associated with cancer, say the researchers.
Dmitry Gordenin, Ph.D., corresponding author of the paper, said that scientists knew the main functions of APOBEC cytosine deaminases
were to inactivate viruses that attack the body and prevent ancient viruses present in the human genome from moving around and causing disrupting mutations.
Non-Giusti methods includes the reduced nicotinamide adenine dinucleotide-linked kinetic method, ADA deaminases adenosine to inosine.
The analysis of pleural fluid adenosine deaminase (ADA) levels in the diagnosis of tuberculous pleural effusion (TPE) was established in 1978 by Piras et al (1).
Adenosine deaminase (ADA) is an enzyme in the purine salvage pathway that catalyses the conversion of adenosine and deoxyadenosine to inosine and deoxyinosine with the release of ammonia.
There are no international standardisation programs for adenosine deaminase assays and published cut-off should therefore be viewed with caution.
However, if clinical details suggest a high pre-test probability, adenosine deaminase results should be interpreted with caution.
Adenosine deaminase activity in pleural effusions: an aid to differential diagnosis.
Diagnostic value of adenosine deaminase in tuberculous pleural effusions: a meta-analysis.